Race Is On for Synthetic Cannabinoids – Bloomberg

Biomedican on Bloomberg

Biomedican on Bloomberg

In the recent article, “Race Is On for Synthetic Cannabinoids: Cannabis Weekly” published in Bloomberg, Tiffany Kary highlighted that increased demand and popularity of cannabis resulted in an increased race for production of synthetic rare cannabinoids. Some companies are scaling up efforts to engineer lesser-known cannabinoids such as CBG and CBN synthetically.

Why rare cannabinoids?

As demand grows for cannabis-derived treatments for sleep, pain relief, and relaxation, every firm strives to improve productivity and reduce cost. This led to the extraction of over 100 cannabinoids, including CBG -increasingly popular for pain and nausea- CBD, CBN, and more. 11% increase in the sale of tinctures with CBN, CBG, THC-A, or THC-V was recorded.

How to produce rare cannabinoids at scale?

Extraction of cannabinoids from plants is a costly and time-consuming method. However, engineering rare cannabinoids yield a pure, cheap, and pharmaceutical grade product.

According to Dennis O’Neil, president at Biomedican, the conventional methods of cannabinoid production involve long and tedious steps, including growing, harvesting, and extracting with the disadvantage of yielding costly and different products every time. This led Biomedican to develop a biosynthesis method that is far safer, efficient, and environmentally friendly. Tiffany mentioned Biomedican’s vision to produce multiple strains at a cost under $1 a gram is far below CBG’s current wholesale price of $20 a gram.

Are those cannabinoids really synthetic?

While biosynthesis may sound very similar to traditional chemical synthesis, it is essential to notice it has nothing in common. Biosynthetic cannabinoids grow naturally within a living organism, making them identical to extracted from plants. In contrast, compounds derived from chemical synthesis often possess components that differ from the desired naturally occurring compounds. Those compounds are generally less stable and, therefore, can result in undesired side effects.

Biomedican is leading the race in producing biosynthetic cannabinoids within proprietary yeast with a strain of CBG ready for wide-scale production. Max Mikheev demonstrated that Biomedican is aimed to ramp up the output of another class of minor cannabinoids within two months. Dennis O’Neil referred biosynthesis approach as the next generation of CBD production. This advanced method employs GMO yeast that produces 100% pure rare cannabinoids without cultivating plants. The final product does not contain any contaminants, which is why Biomedican claims’ its cannabinoids to be organic and GMO-free

At Biomedican, we are inviting investors to participate in producing more organic and natural products while revolutionizing the cannabinoid supply chain and directly feeding into several markets where cannabinoids and terpenes are in high demand.

Saba IqbalAuthor posts

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Comments are disabled.